While no human clinical trials have yet tested Epitalon in cancer therapy, a growing body of animal studies suggests that it may reduce mutation load, normalize gene expression, and delay the onset of tumors, especially in aging or genetically predisposed systems
At reasonable amounts, semaglutide alone usually leads to a 10-15% drop in body weight over 68 weeks
Key Research Points at a Glance A 15-amino-acid fragment of a gastric-juice-derived protective protein, first characterised in the early 1990s Primary research mechanisms: angiogenesis (VEGF pathway) and gastric/gut-lining signalling Secondary mechanisms under study: growth factor modulation (EGF, FGF) and nitric oxide system interaction Frequently co-researched with TB-500 despite acting through an unrelated mechanism The large majority of published research is pre-clinical (in-vitro and animal-model), not human clinical data Notably stable across a wider pH/temperature range than many comparable research peptides What Is BPC-157
Why do researchers study copper-binding peptides
J Clin Invest 37:1176, 1958
